Published in Oncogene on December 01, 2008
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer (2011) 6.32
Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol (2013) 3.11
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science (2013) 2.90
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell (2014) 2.68
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci (2011) 1.91
Where is mTOR and what is it doing there? J Cell Biol (2013) 1.91
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer (2010) 1.80
Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab (2014) 1.73
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50
Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta (2010) 1.50
The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol (2010) 1.49
REPTOR and REPTOR-BP Regulate Organismal Metabolism and Transcription Downstream of TORC1. Dev Cell (2015) 1.46
Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res (2011) 1.44
Rapamycin: one drug, many effects. Cell Metab (2014) 1.41
Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev (2013) 1.40
Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis (2012) 1.40
Phosphorylated Ribosomal Protein S6 Is Required for Akt-Driven Hyperplasia and Malignant Transformation, but Not for Hypertrophy, Aneuploidy and Hyperfunction of Pancreatic β-Cells. PLoS One (2016) 1.38
Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol (2014) 1.34
p53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biol (2013) 1.33
Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol (2012) 1.32
Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther (2011) 1.28
Primary cilia and coordination of receptor tyrosine kinase (RTK) signalling. J Pathol (2011) 1.27
mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science (2016) 1.24
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene (2013) 1.23
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis (2010) 1.19
MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer (2012) 1.13
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther (2012) 1.09
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1.08
Regulation of mTORC1 signaling by pH. PLoS One (2011) 1.04
Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? Redox Biol (2015) 1.02
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res (2016) 1.01
SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer Metab (2014) 1.00
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des (2011) 0.99
Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene (2015) 0.97
Evolution of the TOR pathway. J Mol Evol (2011) 0.95
RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Oncogene (2012) 0.95
mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med (2015) 0.93
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Oncotarget (2015) 0.92
cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Cell Signal (2011) 0.92
Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia (2012) 0.91
Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer (2012) 0.89
Decision-making by p53 and mTOR. Aging (Albany NY) (2010) 0.89
Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR. BMC Cancer (2013) 0.89
Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer (2013) 0.89
mTORC1 signaling activates NRF1 to increase cellular proteasome levels. Cell Cycle (2015) 0.89
Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. Proc Natl Acad Sci U S A (2014) 0.87
Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFκB and Akt/mTOR Signaling Pathways. J Oncol (2012) 0.87
Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness. Oncotarget (2015) 0.87
microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res (2014) 0.87
Glutaminolysis and autophagy in cancer. Autophagy (2015) 0.86
Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer (2016) 0.86
The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas. Adv Hematol (2011) 0.85
New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer (2011) 0.85
The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. J Neuroinflammation (2014) 0.84
Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int J Mol Sci (2013) 0.84
Cell signalling: nutrient sensing lost in cancer. Nature (2013) 0.83
Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis. Oncotarget (2016) 0.83
Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells. Mol Cancer Res (2014) 0.81
Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment. Nutr Cancer (2011) 0.80
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene (2013) 0.80
Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma. Int J Hepatol (2012) 0.79
mTOR activation promotes plasma cell differentiation and bypasses XBP-1 for immunoglobulin secretion. Mol Cell Biol (2014) 0.79
mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress. Cancer Res (2016) 0.79
Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish. Dis Model Mech (2013) 0.78
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. Oncotarget (2016) 0.78
Amino acid management in cancer. Semin Cell Dev Biol (2015) 0.78
Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet (2016) 0.78
Loss of TSC2 confers resistance to ceramide and nutrient deprivation. Oncogene (2013) 0.77
Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia. Cytokine (2016) 0.77
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer (2016) 0.76
KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice. Mol Neurobiol (2016) 0.76
Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients. Oncol Lett (2014) 0.76
S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells. BMC Cancer (2016) 0.76
mTORC1 signaling and the metabolic control of cell growth. Curr Opin Cell Biol (2017) 0.76
Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment. PLoS One (2016) 0.75
MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci Rep (2017) 0.75
Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model. Sci Rep (2016) 0.75
Caspase-mediated cleavage of raptor participates in the inactivation of mTORC1 during cell death. Cell Death Discov (2016) 0.75
MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. Mol Cancer (2017) 0.75
Raptor hunted by caspases. Cell Death Dis (2016) 0.75
Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Front Pharmacol (2016) 0.75
The TOR Signaling Pathway in Spatial and Temporal Control of Cell Size and Growth. Front Cell Dev Biol (2017) 0.75
Formal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer. Front Physiol (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
TOR signaling in growth and metabolism. Cell (2006) 35.29
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 11.50
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Role of autophagy in cancer. Nat Rev Cancer (2007) 10.88
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 10.50
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 10.16
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med (2008) 9.64
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell (1994) 8.71
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol (2007) 8.07
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature (1990) 7.74
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell (2006) 7.49
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell (2005) 6.71
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer (2008) 6.02
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem (1995) 5.57
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol (2002) 5.39
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A (2004) 5.16
Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell (2002) 5.06
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79
Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev (2006) 4.78
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J (2008) 4.49
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol (2006) 4.24
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem (2003) 3.83
Identification of a conserved motif required for mTOR signaling. Curr Biol (2002) 3.78
Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci (2005) 3.77
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol (2008) 3.50
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A (1994) 3.30
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol (2009) 3.25
Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J (2007) 3.08
mTOR and cancer therapy. Oncogene (2006) 3.07
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem (2003) 2.88
Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med (2008) 2.70
Targeting the mTOR signaling network in cancer. Trends Mol Med (2007) 2.66
Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol (2008) 2.58
mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A (2008) 2.50
Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol (2005) 2.47
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol (2004) 2.24
mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 2.08
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res (2006) 1.84
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J Biol Chem (2003) 1.72
4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res (2007) 1.68
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer (2006) 1.68
mTOR is activated in the majority of malignant melanomas. J Invest Dermatol (2007) 1.66
Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol (2007) 1.66
Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res (2009) 1.58
Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate (2006) 1.57
Genomic complexity and plasticity of Burkholderia cepacia. FEMS Microbiol Lett (1996) 2.24
The Kar3p kinesin-related protein forms a novel heterodimeric structure with its associated protein Cik1p. Mol Biol Cell (2000) 1.28
Kynurenine metabolism in rats: some hormonal factors affecting enzyme activities. Life Sci (1975) 0.76